Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) adjuvanted vaccine in older adults with chronic obstructive pulmonary disease (COPD)
T. Wilkinson (Southampton, United Kingdom), S. Schembri (Dundee, United Kingdom), C. Brightling (Leicester, United Kingdom), N. Bakerly (Salford, United Kingdom), W. Macnee (Edinburgh, United Kingdom), L. Rombo (Uppsala, Sweden), J. Hedner (Göteborg, Sweden), M. Allen (Stoke-on-Trent, United Kingdom), P. Walker (Liverpool, United Kingdom), I. De Ryck (Siena, Italy), A. Tasciotti (Siena, Italy), D. Casula (Siena, Italy), M. Testa (Siena, Italy), A. Arora (Siena, Italy)
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Session: COPD exacerbations and bronchiectasis
Session type: Thematic Poster
Number: 4089
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Wilkinson (Southampton, United Kingdom), S. Schembri (Dundee, United Kingdom), C. Brightling (Leicester, United Kingdom), N. Bakerly (Salford, United Kingdom), W. Macnee (Edinburgh, United Kingdom), L. Rombo (Uppsala, Sweden), J. Hedner (Göteborg, Sweden), M. Allen (Stoke-on-Trent, United Kingdom), P. Walker (Liverpool, United Kingdom), I. De Ryck (Siena, Italy), A. Tasciotti (Siena, Italy), D. Casula (Siena, Italy), M. Testa (Siena, Italy), A. Arora (Siena, Italy). Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) adjuvanted vaccine in older adults with chronic obstructive pulmonary disease (COPD). 4089
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Clinical impact of a non-typeable Haemophilus influenzae (NTHi) adjuvanted vaccine in adults with chronic obstructive pulmonary disease (COPD) Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) and M. catarrhalis (Mcat) adjuvanted vaccines in adults Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018
Alteration of the immune response to nontypeable haemophilus influenzae (NTHI) during COPD exacerbation in mice Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013
Infection pattern and inflammatory response in acute and persistent nontypeable haemophilus influenzae (NTHi) infection of COPD lung tissue Source: Eur Respir J 2006; 28: Suppl. 50, 841s Year: 2006
Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Source: Eur Respir J 2002; 20: 813-818 Year: 2002
Influenza and pneumococcal vaccines prevalence and their influance on asthma and chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Effectiveness of polysaccharide pneumococcal vaccination among subjects with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 442s Year: 2006
HI-164, an oral vaccine to non-typable haemophilus influenzae , reduces antibiotic use, respiratory exacerbations and hospitalisations in patients with COPD Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Pneumococcal vaccination coverage in Spanish patients with chronic obstructive pulmonary disease (COPD). Result of the EPIDEPOC study Source: Eur Respir J 2004; 24: Suppl. 48, 144s Year: 2004
Non-typeable Haemophilus influenzae infection of ciliated epithelium from healthy and chronic obstructive pulmonary disease donors Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018
Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 178s Year: 2006
Late Breaking Abstract - Seroprevalence of Bordetella pertussis in chronic obstructive pulmonary disease (COPD) patients Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020
Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002
Pneumococcal vaccination: Effects on exacerbation of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 372s Year: 2007
Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13) Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
Clinical efficacy of pneumococcal conjugate vaccine in patients with chronic airway disease Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014
Pneumococcal vaccine in steroid-dependent COPD Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005